Relmada Therapeutics is a small cap biopharmaceutical company with four products in clinical development to treat pain. Relmada combines proven drug candidates with novel delivery methods and pharmaceutical compositions to reduce clinical development time and costs and lower regulatory risks to deliver therapeutic products targeting areas of high unmet need. The company has an efficient strategy, in our opinion, of utilizing the 505(b)(2) pathway to develop its drugs, which lowers the risk of drug development. The 505(b)(2) approval process is designed specifically to address new formulations of previously approved drugs, thus it has the potential to be more cost efficient and expeditious to market. However, as the drug d-Methadone has not been already approved by the FDA, its regulatory pathway to approval will be via the more traditional NDA development, which will consist of conducting a full clinical development program. Other products in clinical development include LevoCap ER (Levorphanol ER), an extended release abuse resistant pain medication for pain severe enough to require daily, around the clock opioid treatment, MepiGel (Mepivacaine gel), a non-greasy topical gel for use as a local anesthetic for post-therapeutic neuralgia and HIV-associated neuropathy, and BuTab ER (Buprenorphine ER), a Class-III opioid with low abuse potential for moderate chronic pain and potentially opioid addiction. These three products are expected to only require a small Phase I/II trial prior to a pivotal Phase III registration program.
Relmada commenced operations on May 24, 2004 as a Delaware limited liability company (LLC) under the name of TheraQuest Biosciences, LLC. In February 2007, the company converted from an LLC to a C Corporation. In November 2011, it changed its name to Relmada Therapeutics, Inc. On May 20, 2014, Relmada became public through a reverse merger with Camp Nine, Inc. Camp Nine was formed as a Nevada corporation on May 31, 2012. Relmada completed a share exchange in May 2014 with Camp Nine. Relmada became a wholly-owned subsidiary of Camp Nine when the shareholders of Relmada exchanged 10 shares of Relmada common stock for 1 share of Camp Nine common stock in connection with the share exchange. Camp Nine changed its name to Relmada on July 8, 2014, which became effective in accordance with the Certificate of Amendment to Articles of Incorporation filed with the State of Nevada. On August 5, 2014, FINRA approved the name change and the changing of the ticker symbol to RLMD, which became effective on August 6, 2014.